Two vaccines which can be used as an immunization against Zika virus were developed by an Indian biotechnology company, according to scientists.

"On Zika, we are probably the first vaccine company in the world to file a vaccine candidate patent about nine months ago," Krishna Ella, Bharat Biotech managing director said in an interview.

RT reported the vaccines are expected to help the body produce strong antibodies which could be its primary defense against the Zika virus. The vaccines are developed by Bharat Biotech International in Hyderabad, India. Their research started around nine months ago after the company has legally imported a live Zika virus to be used in their study.

According to the Wall Street Journal, Bharat Biotech created the vaccine by making an "attenuated version of a virus." The process includes straining of the Zika virus making it weak enough to be safely used by humans as a vaccine. The vaccines are scheduled to be tested in animals first, then, after it turned out successful, will undergo human trials.

According to Ella, the vaccine will undergo laboratory testing and if trials are successful, the world can already expect a vaccine against Zika virus four months from now. She also added that the company is willing to make one million of doses by that time.

"The prime minister should take up this project as it helps communities like Brazil and Colombia where we can do vaccine diplomacy," Ella said. "We would love to help. We want global public health to benefit," he added.

Public officials said that any newly created vaccine should pass through a process of screening before allowing it to be distributed among people. Soumya Swaminathan, Indian Council for Medical Research's director general, said drug testing usually takes two to three years to finalize.

"We have to encourage indigenous drug manufacturers," said Dr. Swaminathan. But "we cannot bypass any steps in clinical development," he added.

Meanwhile, Sanofi SA, a France-based pharmaceutical giant, said their company is about to start their research by using their newly-approved dengue vaccine as a basis of creating one for the Zika virus.

As to what some scientists said, creating a vaccine against Zika could be complicated because of its similarity with dengue. They warned all the companies who are presently working on the vaccine to test whether the vaccine is also effective to people who are already exposed to dengue virus and other mosquito-borne viruses or not.